Home » Newsletters » BioWorld Science

BioWorld Science

Aug. 30, 2006

View Archived Issues

Plasmacytoid DCs regarded as targets for microbicides

Novel dual PPARgamma/delta agonist controls dyslipidemia and hyperglycemia in diabetes

Recent Vernalis patent reports novel analgesic agents

Novel agents for treating neurological disorders disclosed in recent patent literature

Recent patents report novel therapeutic agents for hepatitis C virus infection

New peptidomimetic C5a receptor antagonist displays superior selectivity and in vivo activity

Ingested SIRS effective in preclinical models of type 1 diabetes and EAE

Gabapentin may be effective in treatment of neurogenic overactive bladder

Recent patents describe new treatment strategies for diabetes

Novogen offers overview of year's highlights

Allos completes enrollment in pivotal study of Efaproxyn

MedImmune and Infinity team up to develop small molecule cancer drugs

Colazal receives pediatric exclusivity

Milestones at BioMarin

SGX discontinues phase II/III study of Troxatyl in third-line AML

Enrollment completed in U.S. phase III study of Aridol

Six-week follow-up completed in study of Cethrin in acute spinal cord injury

Sinovac Biotech reports preliminary phase I trial of pandemic influenza vaccine

Nigerian phase III study of Savvy ended early

Rituxan shows benefit in relapsing-remitting MS

Extina shows non-inferiority versus ketoconazole cream in seborrheic dermatitis

Review extended for desvenlafaxine succinate NDA

Gestiva recommended for approval to prevent preterm birth

E.U. approval for Exjade

Advances in anti-HIV microbicides reported at the recent AIDS conference

Resistance to peginterferon/ribavirin conferred by increased expression of interferon genes

ITMN-191 continues preclinical development, clinical trials warranted

Rapamycin shows efficacy against Listeria monocytogenes infection in mice

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for March 10, 2026.
Cas and effect: Merck’s phase III ripples HIF-2α space
BioWorld
Oddsmakers wasted no time figuring the market chances after Merck & Co. Inc. rolled out data from the phase III Litespark-011 study testing its oral...
Brain’s hidden tau-clearing pathway uncovered
BioWorld Science
Researchers at INSERM and collaborators have identified hypothalamic tanycytes as mediators of tau clearance and shown that their structural and genetic...
News in brief
BioWorld Asia
BioWorld Asia briefs for March 10, 2026
MSD synthesizes α-synuclein PET agents
BioWorld Science
Merck Sharp & Dohme LLC (MSD) has prepared and tested new positron emission tomography (PET) agents for binding and imaging α-synuclein (SNCA) for the diagnosis...